Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maribavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.96 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.40 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maribavir SCHEMBL4936315 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL18459376 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL7634766 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL13082009 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL13641210 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL7634149 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL18459197 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL1028527 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL13640277 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A | |
| Maribavir SCHEMBL7895798 | 0.98 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | claimed |
| US-20130261294-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLAXOSMITHKLINE LLC (US) | 2013-10-03 | — | — | US | claimed |
| US-20020177703-A1 | Novel crystalline forms of an antiviral benzimidazole compound | GLOVER BOBBY NEAL (US) | 2002-11-28 | — | — | US | claimed |
| US-6469160-B1 | 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H -BENZIMIDAZOLE (AKA 1263W94) OF GIVEN X-RAY DIFFRACTION PATTERN | SMITHKLINE BEECHAM CORPORATION | 2002-10-22 | — | — | US | claimed |
| EP-1071693-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 2001-01-31 | — | — | EP | claimed |
| WO-1999051618-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 1999-10-14 | — | — | WO | claimed |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170002035-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (GB) | 2017-01-05 | — | — | US | disclosed |
| US-20160030460-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9163052-B2 | Crystalline forms of an antiviral benzimidazole compound | GLAXOSMITHKLINE LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130261294-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLAXOSMITHKLINE LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20110118203-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLAXOSMITHKLINE LLC | 2011-05-19 | — | — | US | disclosed |
| US-20100179101-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLOVER BOBBY NEAL | 2010-07-15 | — | — | US | disclosed |
| US-20020177703-A1 | Novel crystalline forms of an antiviral benzimidazole compound | GLOVER BOBBY NEAL (US) | 2002-11-28 | — | — | US | disclosed |
| US-6482939-B1 | Form vi 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)-1h-bezimimidazole | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-6469160-B1 | 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H -BENZIMIDAZOLE (AKA 1263W94) OF GIVEN X-RAY DIFFRACTION PATTERN | SMITHKLINE BEECHAM CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1071693-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 2001-01-31 | — | — | EP | disclosed |
| EP-1070078-A2 | FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | GLAXO GROUP LIMITED (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051618-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051617-A2 | FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | GLAXO GROUP LIMITED (GB) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179101-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 96/4885SLC15A1 2805/4885HSPA5 1423/4885 |
| US-20110118203-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885SLC15A1 2842/4885HSPA5 1294/4885 |
| US-20130261294-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 96/4885SLC15A1 2805/4885HSPA5 1423/4885 |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885SLC15A1 2842/4885HSPA5 1294/4885 |
| US-20020177703-A1 | Novel crystalline forms of an antiviral benzimidazole compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 50/4885SLC15A1 2526/4885HSPA5 1331/4885 |
| US-20170002035-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885SLC15A1 2842/4885HSPA5 1294/4885 |
| US-20160030460-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885SLC15A1 2842/4885HSPA5 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.